Cardiff Oncology Inc. (CRDF)
CRDF trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/0001193125-26-067464-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRDF on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001213037 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $593K |
| Net income | -$45.9M |
| Operating income | -$49.0M |
| Net margin | -7732.0% |
| Operating margin | -8256.3% |
| Revenue growth | -13.2% |
| Cash | $17.5M |
| Total assets | $61.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 111.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $12.1M cash; operating cash flow -$10.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 77,795,249 (2026-11-03); 67,360,564 a year earlier; 44,677,169 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-07-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-02-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.1M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $171K | -$8.9M | -$9.9M | $12.1M | No debt tags | $559K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $104K | -$9.2M | -$11.8M | $9.2M | No debt tags | $508K | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $41K | -$12.3M | -$12.3M | $8.5M | No debt tags | $525K | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $243K | -$7.2M | -$6.0M | $17.5M | No debt tags | $593K | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $120K | -$11.3M | -$10.8M | $10.1M | No debt tags | $501K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $121K | -$13.9M | -$8.3M | $10.8M | No debt tags | $546K | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $109K | -$13.4M | -$12.8M | $24.1M | No debt tags | $588K | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $151K | -$11.8M | -$10.3M | $51.5M | No debt tags | $684K | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-16 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-08-26 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.8% |
| 1 month | -27.7% |
| 3 months | -25.5% |
| Year to date | -74.0% |
| 1 year | -66.0% |
| From 52-week high | -77.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.3336 | -4.47% | $76.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier